Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
Abstract The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of
rapamycin (mTOR) represent two vital intracellular signaling pathways, which are …
rapamycin (mTOR) represent two vital intracellular signaling pathways, which are …
The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells
I Nepstad, KJ Hatfield, IS Grønningsæter… - International journal of …, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …
Cancer stem cells
Cancer Stem Cells | New England Journal of Medicine Skip to main content The New England
Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical …
Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical …
mTOR signaling in disease
E Dazert, MN Hall - Current opinion in cell biology, 2011 - Elsevier
The target of rapamycin (TOR) is a highly conserved serine/threonine kinase and a central
controller of cell growth, metabolism and aging. Mammalian TOR (mTOR) is activated in …
controller of cell growth, metabolism and aging. Mammalian TOR (mTOR) is activated in …
Oxidative stress, redox regulation and diseases of cellular differentiation
Background Within cells, there is a narrow concentration threshold that governs whether
reactive oxygen species (ROS) induce toxicity or act as second messengers. Scope of …
reactive oxygen species (ROS) induce toxicity or act as second messengers. Scope of …
The increasing complexity of the cancer stem cell paradigm
The investigation and study of cancer stem cells (CSCs) have received enormous attention
over the past 5 to 10 years but remain topics of considerable controversy. Opinions about …
over the past 5 to 10 years but remain topics of considerable controversy. Opinions about …
Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence
S Darici, H Alkhaldi, G Horne, HG Jørgensen… - Journal of Clinical …, 2020 - mdpi.com
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
J Zhou, J Wulfkuhle, H Zhang, P Gu… - Proceedings of the …, 2007 - National Acad Sciences
Side-population (SP) cells within cancers and cell lines are rare cell populations known to
enrich cancer stem-like cells. In this study, we characterized SP cells from the human breast …
enrich cancer stem-like cells. In this study, we characterized SP cells from the human breast …
Targeting PI3K/AKT/mTOR network for treatment of leukemia
J Bertacchini, N Heidari, L Mediani, S Capitani… - Cellular and molecular …, 2015 - Springer
Objective Increased activity of PI3K/AKT/mTOR pathway has been observed in a huge
number of malignancies. This pathway can function as a prosurvival factor in leukemia stem …
number of malignancies. This pathway can function as a prosurvival factor in leukemia stem …
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
R Tibes, YH Qiu, Y Lu, B Hennessy, M Andreeff… - Molecular cancer …, 2006 - AACR
Proteomics has the potential to provide answers in cancer pathogenesis and to direct
targeted therapy through the comprehensive analysis of protein expression levels and …
targeted therapy through the comprehensive analysis of protein expression levels and …